Table 2.
Baseline demographics and disease characteristics for patients receiving an angiotensin receptor blockers or an angiotensin-converting enzyme inhibitor monotherapy
| ARB monotherapy |
ACEI monotherapy |
|||
|---|---|---|---|---|
| Parameter | Lumiracoxib 100 mg od (N = 57) | Ibuprofen 600 mg tid (N = 48) | Lumiracoxib 100 mg od (N = 42) | Ibuprofen600 mg tid (N = 40) |
| Age (years), mean ± SD | 64.3 ± 8.4 | 64.6 ± 9.0 | 64.1 ± 7.6 | 61.0 ± 6.7 |
| Range (min–max) | 50–86 | 50–85 | 50–83 | 50–77 |
| Age group, n (%) | ||||
| ≤ 64 years | 30 (52.6) | 24 (50.0) | 23 (54.8) | 28 (70.0) |
| 65–74 years | 19 (33.3) | 16 (33.3) | 15 (35.7) | 11 (27.5) |
| ≥ 75 years | 8 (14.0) | 8 (16.7) | 4 (9.5) | 1 (2.5) |
| Gender, n (%) | ||||
| Female | 41 (71.9) | 35 (72.9) | 22 (52.4) | 28 (70.0) |
| Male | 16 (28.1) | 13 (27.1) | 20 (47.6) | 12 (30.0) |
| Race, n (%) | ||||
| Caucasians | 56 (98.2) | 45 (93.8) | 38 (90.5) | 39 (97.5) |
| Black/African Americans | 1 (1.8) | 2 (4.2) | 1 (2.4) | 1 (2.5) |
| Others | 0 (0.0) | 1 (2.1) | 3 (7.1) | 0 (0.0) |
| Duration of OA (years), mean ± SD | 4.9 ± 5.3 | 6.7 ± 7.0 | 4.5 ± 6.0 | 5.0 ± 5.3 |
| OA pain, n (%) | ||||
| Mild | 5 (8.8) | 6 (12.5) | 9 (21.4) | 10 (25.0) |
| Moderate | 31 (54.4) | 23 (47.9) | 19 (45.2) | 14 (35.0) |
| Severe | 21 (36.8) | 19 (39.6) | 14 (33.3) | 16 (40.0) |
| Patient’s global assessment of disease activity, n (%) | ||||
| Very good | 0 (0.0) | 1 (2.1) | 0 (0.0) | 4 (10.0) |
| Good | 6 (10.5) | 9 (18.8) | 12 (28.6) | 4 (10.0) |
| Fair | 33 (57.9) | 30 (62.5) | 18 (42.9) | 22 (55.0) |
| Poor | 18 (31.6) | 8 (16.7) | 12 (28.6) | 10 (25.0) |
| Very poor | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Physician’s global assessment of disease activity, n (%) | ||||
| Very good | 1 (1.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Good | 2 (3.5) | 6 (12.5) | 8 (19.0) | 12 (30.0) |
| Fair | 41 (71.9) | 31 (64.6) | 26 (61.9) | 20 (50.0) |
| Poor | 13 (22.8) | 11 (22.9) | 8 (19.0) | 8 (20.0) |
| Very poor | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Duration of hypertension (years), mean ± SD | 6.9 ± 6.6 | 6.2 ± 5.9 | 7.5 ± 7.8 | 6.3 ± 5.4 |
| Sitting BP* (mmHg), mean ± SD | ||||
| Systolic | 130.5 ± 7.2 | 129.1 ± 8.5 | 131.1 ± 6.5 | 129.7 ± 10.0 |
| Diastolic | 77.8 ± 7.0 | 77.7 ± 8.0 | 78.9 ± 6.0 | 77.8 ± 6.8 |
| 24-h ambulatory BP (mmHg), mean ± SD | ||||
| Systolic | 127.2 ± 12.4 | 127.4 ± 12.1 | 131.1 ± 12.0 | 127.6 ± 12.2 |
| Diastolic | 75.6 ± 8.2 | 75.8 ± 7.7 | 77.4 ± 7.7 | 75.9 ± 7.9 |
*
As measured by office cuff sphygmomanometer.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; BP, blood pressure; OA, osteoarthritis; od, once daily; SD, standard deviation; tid, thrice daily.